Management of candidaemia and invasive candidiasis in critically ill patients

International Journal of Antimicrobial Agents

Volumn 42, Issue SUPPL.1, 2013, Pages

  Chahoud, Jad ^a   Kanafani, Zeina A ^a   Kanj, Souha S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Antifungal; Candidaemia; Catheter; Critical care; Diagnosis; Management; Prophylaxis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BIOLOGICAL MARKER; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDEMIA; CATHETER REMOVAL; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; PATIENT DECISION MAKING; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; CANDIDEMIA; CANDIDIASIS, INVASIVE; CHEMOPREVENTION; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS;

EID: 84879106397     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.04.008     Document Type: Article

References (68)

1. J.L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, and C.D. Martin International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
2. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
3. H. Wisplinghoff, T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317
4. O. Gudlaugsson, S. Gillespie, K. Lee, J. Vande Berg, J. Hu, and S. Messer Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 2003 1172 1177
5. D.L. Horn, D. Neofytos, E.J. Anaissie, J.A. Fishman, W.J. Steinbach, and A.J. Olyaei Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance registry Clin Infect Dis 48 2009 1695 1703
6. D.H. Kett, E. Azoulay, P.M. Echeverria, and J.L. Vincent Candida bloodstream infections in intensive care units: analysis of the Extended Prevalence of Infection in Intensive Care Unit Study Crit Care Med 39 2011 665 670
7. J. Morgan, M.I. Meltzer, B.D. Plikaytis, A.N. Sofair, S. Huie-White, and S. Wilcox Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance Infect Control Hosp Epidemiol 26 2005 540 547
8. T.E. Zaoutis, J. Argon, J. Chu, J.A. Berlin, T.J. Walsh, and C. Feudtner The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis Clin Infect Dis 41 2005 1232 1239
9. M.C. Arendrup, B. Bruun, J.J. Christensen, K. Fuursted, H.K. Johansen, and P. Kjaeldgaard National surveillance of fungemia in Denmark (2004 to 2009) J Clin Microbiol 49 2011 325 334
10. A.M. Tortorano, C. Kibbler, J. Peman, H. Bernhardt, L. Klingspor, and R. Grillot Candidaemia in Europe: epidemiology and resistance Int J Antimicrob Agents 27 2006 359 366
11. M.E. Bougnoux, G. Kac, P. Aegerter, C. d'Enfert, and J.Y. Fagon Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome Intensive Care Med 34 2008 292 299
12. D.J. Diekema, S.A. Messer, A.B. Brueggemann, S.L. Coffman, G.V. Doern, and L.A. Herwaldt Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study J Clin Microbiol 40 2002 1298 1302
13. R. Hachem, H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy Cancer 112 2008 2493 2499
14. G.H. Pereira, P.R. Muller, M.W. Szeszs, A.S. Levin, and M.S. Melhem Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species Med Mycol 48 2010 839 842
15. M.A. Pfaller, G.J. Moet, S.A. Messer, R.N. Jones, and M. Castanheira Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) J Clin Microbiol 49 2011 396 399
16. M.C. Arendrup, K. Fuursted, B. Gahrn-Hansen, H.C. Schonheyder, J.D. Knudsen, and I.M. Jensen Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility Clin Microbiol Infect 14 2008 487 494
17. J. Nolla-Salas, A. Sitges-Serra, C. León-Gil, J. Martínez-González, M.A. León-Regidor, and P. Ibáñez-Lucía Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU Intensive Care Med 23 1997 23 30
18. J. Garnacho-Montero, J.L. Garcia-Garmendia, A. Barrero-Almodovar, F.J. Jimenez-Jimenez, C. Perez-Paredes, and C. Ortiz-Leyba Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis Crit Care Med 31 2003 2742 2751
19. E.H. Ibrahim, G. Sherman, S. Ward, V.J. Fraser, and M.H. Kollef The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting Chest 118 2000 146 155
20. J. Garbino, D.P. Lew, J.A. Romand, S. Hugonnet, R. Auckenthaler, and D. Pittet Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination Intensive Care Med 28 2002 1708 1717
21. D. Pittet, M. Monod, P.M. Suter, E. Frenk, and R. Auckenthaler Candida colonization and subsequent infections in critically ill surgical patients Ann Surg 220 1994 751 758
22. G.A. Lamaris, B. Esmaeli, G. Chamilos, A. Desai, R.F. Chemaly, and I.I. Raad Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases Eur J Clin Microbiol Infect Dis 27 2008 343 347
23. O. Leroy, J.P. Gangneux, P. Montravers, J.P. Mira, F. Gouin, and J.P. Sollet Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006) Crit Care Med 37 2009 1612 1618
24. M. Prella, J. Bille, M. Pugnale, B. Duvoisin, M. Cavassini, and T. Calandra Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies Diagn Microbiol Infect Dis 51 2005 95 101
25. L. Ostrosky-Zeichner, C. Sable, J. Sobel, B.D. Alexander, G. Donowitz, and V. Kan Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting Eur J Clin Microbiol Infect Dis 26 2007 271 276
26. N.I. Paphitou, L. Ostrosky-Zeichner, and J.H. Rex Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials Med Mycol 43 2005 235 243
27. H.M. Blumberg, W.R. Jarvis, J.M. Soucie, J.E. Edwards, J.E. Patterson, and M.A. Pfaller Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey Clin Infect Dis 33 2001 177 186
28. S.B. Wey, M. Mori, M.A. Pfaller, R.F. Woolson, and R.P. Wenzel Risk factors for hospital-acquired candidemia. A matched case-control study Arch Intern Med 149 1989 2349 2353
29. C. León, S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, and F. Alvarez-Lerma A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization Crit Care Med 34 2006 730 737
30. H. Dupont, A. Bourichon, C. Paugam-Burtz, J. Mantz, and J.M. Desmonts Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31 2003 752 757
31. M. Ellis, B. Al-Ramadi, R. Bernsen, J. Kristensen, H. Alizadeh, and U. Hedstrom Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever J Med Microbiol 58 2009 606 615
32. D.E. Karageorgopoulos, E.K. Vouloumanou, F. Ntziora, A. Michalopoulos, P.I. Rafailidis, and M.E. Falagas β-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis Clin Infect Dis 52 2011 750 770
33. T. Avni, L. Leibovici, and M. Paul PCR diagnosis of invasive candidiasis: systematic review and meta-analysis J Clin Microbiol 49 2011 665 670
34. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr., T.F. Calandra, and J.E. Edwards Jr. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
35. T. Calandra, and O. Marchetti Clinical trials of antifungal prophylaxis among patients undergoing surgery Clin Infect Dis 39 Suppl. 4 2004 S185 S192
36. M. Cruciani, F. de Lalla, and C. Mengoli Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis Intensive Care Med 31 2005 1479 1487
37. P.A. Lipsett Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations Clin Infect Dis 39 Suppl. 4 2004 S193 S199
38. E.G. Playford, A.C. Webster, T.C. Sorrell, and J.C. Craig Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials J Antimicrob Chemother 57 2006 628 638
39. A.F. Shorr, K. Chung, W.L. Jackson, P.E. Waterman, and M.H. Kollef Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Crit Care Med 33 2005 1928 1935 quiz 1936
40. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients., Am J Med 1989, 86, 668-72.
41. P.A. Pizzo, K.J. Robichaud, F.A. Gill, and F.G. Witebsky Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia Am J Med 72 1982 101 111
42. M. Bassetti, M. Mikulska, and C. Viscoli Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit Crit Care 14 2010 244
43. R. Piarroux, F. Grenouillet, P. Balvay, V. Tran, G. Blasco, and L. Millon Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients Crit Care Med 32 2004 2443 2449
44. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, and D. Kumar Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482
45. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
46. E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, C. Barrios, and D. Raghunadharao Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
47. J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, C.M. van der Horst, and J.E. Edwards A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute N Engl J Med 331 1994 1325 1330
48. J.H. Rex, P.G. Pappas, A.W. Karchmer, J. Sobel, J.E. Edwards, and S. Hadley A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 2003 1221 1228
49. B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, and J.H. Rex Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442
50. P.G. Pappas, C.M. Rotstein, R.F. Betts, M. Nucci, D. Talwar, and J.J. De Waele Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 2007 883 893
51. P.G. Pappas, J.H. Rex, J.D. Sobel, S.G. Filler, W.E. Dismukes, and T.J. Walsh Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 189
52. E.J. Anaissie, R.O. Darouiche, D. Abi-Said, O. Uzun, J. Mera, and L.O. Gentry Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature Clin Infect Dis 23 1996 964 972
53. A. Gafter-Gvili, L. Vidal, E. Goldberg, L. Leibovici, and M. Paul Treatment of invasive candidal infections: systematic review and meta-analysis Mayo Clin Proc 83 2008 1011 1021
54. E.J. Mills, D. Perri, C. Cooper, J.B. Nachega, P. Wu, and I. Tleyjeh Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis Ann Clin Microbiol Antimicrob 8 2009 23
55. P. Phillips, S. Shafran, G. Garber, C. Rotstein, F. Smaill, and I. Fong Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group Eur J Clin Microbiol Infect Dis 16 1997 337 345
56. M. Abele-Horn, A. Kopp, U. Sternberg, A. Ohly, A. Dauber, and W. Russwurm A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients Infection 24 1996 426 432
57. M. Driessen, J.B. Ellis, P.A. Cooper, S. Wainer, F. Muwazi, and D. Hahn Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial Pediatr Infect Dis J 15 1996 1107 1112
58. P. Kujath, K. Lerch, P. Kochendorfer, and C. Boos Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses Infection 21 1993 376 382
59. J.E. Bennett Echinocandins for candidemia in adults without neutropenia N Engl J Med 355 2006 1154 1159
60. T.J. Walsh Echinocandins - an advance in the primary treatment of invasive candidiasis N Engl J Med 347 2002 2070 2072
61. L. Ostrosky-Zeichner, J.H. Rex, P.G. Pappas, R.J. Hamill, R.A. Larsen, and H.W. Horowitz Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 2003 3149 3154
62. J.J. De Waele, D. Vogelaers, S. Blot, and F. Colardyn Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy Clin Infect Dis 37 2003 208 213
63. L.A. Mermel, M. Allon, E. Bouza, D.E. Craven, P. Flynn, and N.P. O'Grady Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 49 2009 1 45
64. E.P. Brass, and J.E. Edwards Should the guidelines for management of central venous catheters in patients with candidemia be changed now? Clin Infect Dis 51 2010 304 306
65. M. Nucci, E. Anaissie, R.F. Betts, B.F. Dupont, C. Wu, and D.N. Buell Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials Clin Infect Dis 51 2010 295 303
66. T.J. Walsh, and J.H. Rex All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters Clin Infect Dis 34 2002 600 602
67. G. Ramage, K. VandeWalle, S.P. Bachmann, B.L. Wickes, and J.L. López-Ribot In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies Antimicrob Agents Chemother 46 2002 3634 3636
68. D.R. Andes, N. Safdar, J.W. Baddley, G. Playford, A.C. Reboli, and J.H. Rex Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials Clin Infect Dis 54 2012 1110 1122